March 12 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF ROCKLATAN(NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - COMPANY PLANS TO LAUNCH ROCKLATAN IN UNITED STATES IN Q2 OF 2019.
Full Article
Feb 25 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, PROVIDES 2019 CASH BURN GUIDANCE AND BUSINESS UPDATE.Q4 ADJUSTED LOSS PER SHARE $0.92.Q4 GAAP LOSS PER SHARE $1.14.Q4 EARNINGS PER SHARE ESTIMATE $-0.87 -- REFINITIV IBES DATA.AERIE PHARMACEUTICALS - GUIDANCE FOR 2019 FULL-YEAR CASH BURN IS CONSISTENT WITH FULL-YEAR 2018 ACTUAL RESULTS, IN RANGE OF $210 MILLION TO $220 MILLION.ENTERING 2019 VERY WELL FINANCED, WITH OVER $300 MILLION IN AVAILABLE LIQUIDITY.Q4 REVENUE $14.5 MILLION.
Full Article
Aug 22 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS INC FILES PROSPECTUS SUPPLEMENT RELATES TO OFFERING OF 329,124 SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.
Full Article
Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 ADJUSTED LOSS PER SHARE $1.14.Q2 GAAP LOSS PER SHARE $1.40.Q2 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.AERIE PHARMACEUTICALS - $286.1 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30.AERIE PHARMACEUTICALS - REITERATED 2018 RHOPRESSA NET REVENUES, TOTAL 2018 CASH BURN GUIDANCE.
Full Article
Aug 1 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS, INC. AND DSM BIOMEDICAL, INC. EXPAND COLLABORATION AGREEMENT FOCUSED ON NOVEL DRUG DELIVERY TECHNOLOGY IN OPHTHALMOLOGY.AERIE PHARMACEUTICALS - PAID $6.0 MILLION TO DSM UPON SIGNING OF EXPANDED AGREEMENT, WITH AN ADDITIONAL $9.0 MILLION PAYABLE TO DSM THROUGH END OF 2020.AERIE PHARMACEUTICALS - TO HAVE EXCLUSIVE LICENSE FOR OPHTHALMIC INDICATIONS TO DSM'S POLYESTERAMIDE POLYMER TECHNOLOGY FOR UNLIMITED NUMBER OF COMPOUNDS.AERIE PHARMACEUTICALS INC - AERIE AND DSM WILL CONTINUE COLLABORATIVE RESEARCH ACTIVITIES THROUGH END OF 2020.AERIE PHARMACEUTICALS - WILL GAIN ACCESS TO DSM'S PRECLINICAL STAGE LATANOPROST IMPLANT WITH POTENTIAL FOR INITIAL CLINICAL STUDIES IN GLAUCOMA PATIENTS IN 2019.
Full Article
July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES DEERFIELD’S CONVERSION OF CONVERTIBLE NOTES INTO AERIE COMMON STOCK AND ESTABLISHMENT OF AN UNDRAWN $100M CREDIT FACILITY WITH DEERFIELD.ENTERED INTO A $100 MILLION SENIOR SECURED DELAYED DRAW TERM LOAN FACILITY WITH AFFILIATES OF DEERFIELD.CREDIT FACILITY MATURES ON JULY 23, 2024.
Full Article
July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES EARLY NOTIFICATION OF FDA ACCEPTANCE OF NDA SUBMISSION FOR ROCLATAN™ (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% WITH PDUFA DATE SET FOR MARCH 14, 2019.AERIE - "DAY 74" NOTIFICATION INDICATED THAT FDA HAS NOT IDENTIFIED ANY POTENTIAL REVIEW ISSUES.AERIE PHARMACEUTICALS INC - "DAY 74" NOTIFICATION DID NOT MENTION NEED FOR AN ADVISORY COMMITTEE.
Full Article
July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES EARLY NOTIFICATION OF FDA ACCEPTANCE OF NDA SUBMISSION FOR ROCLATAN™ (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% WITH PDUFA DATE SET FOR MARCH 14, 2019.AERIE - "DAY 74" NOTIFICATION INDICATED THAT FDA HAS NOT IDENTIFIED ANY POTENTIAL REVIEW ISSUES.AERIE PHARMACEUTICALS INC - "DAY 74" NOTIFICATION DID NOT MENTION NEED FOR AN ADVISORY COMMITTEE.
Full Article
May 15 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%.AERIE PHARMACEUTICALS - EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS.AERIE PHARMACEUTICALS INC - NDA SUBMITTED AS A 505(B)(2) WITH AN EXPECTED TEN-MONTH FDA REVIEW.
Full Article
April 30 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%.AERIE - FORMULARY CONTRACTS FOR COMMERCIAL INSURANCE COVERAGE IN 2018, MEDICARE PART D PROGRAM COVERAGE BEGINNING 2019 IN FINAL STAGES OF EXECUTION.
Full Article
Earnings vs. 
Estimates